Group 1 - The National Healthcare Security Administration (NHSA) has established a pricing mechanism for newly launched drugs and medical devices, including over 100 price items related to new medical technologies, particularly supporting the clinical application and pricing of brain-computer interface (BCI) technology [1][2] - The NHSA issued the "Guidelines for the Pricing of Neurological Medical Services (Trial)" on March 12, which specifically includes pricing items for BCI technologies such as "invasive BCI implantation fee," "invasive BCI removal fee," and "non-invasive BCI adaptation fee" [1][2] - The pricing standardization for BCI projects provides clarity for companies on how to charge, which is expected to facilitate the implementation of new technologies in medical institutions [3] Group 2 - Provinces such as Hubei, Zhejiang, and Jiangsu have announced BCI-related medical service pricing, with fees for non-invasive BCI adaptation set at 966 yuan per session, invasive BCI implantation at 6,600 yuan per session, and invasive BCI removal at 3,200 yuan per session in Jiangsu [2] - The global market for BCI medical applications is projected to reach $40 billion by 2030 and $145 billion by 2040, indicating significant growth potential in the downstream application market [3] - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in the BCI sector, with MicroPort holding a significant market share in China's neuro-interventional medical device market and Heartway recently completing animal trials for an invasive BCI [4]
港股概念追踪 | 国家医保局支持脑机接口技术进入临床并收费 商业化应用落地有望加速(附概念股)
智通财经网·2025-07-31 23:21